Generic Drugs

Business

Dr Reddy's Plans to Disrupt Weight-Loss Market with Generic Wegovy at 60% Discount

Indian pharmaceutical giant Dr Reddy's Laboratories has announced its intention to launch a generic version of Novo Nordisk's blockbuster weight-loss drug Wegovy at a price roughly 60% lower than the branded version, pending regulatory approval. The move could dramatically expand access to obesity treatments in India and other price-sensitive markets.

Feb 17, 2026

Business

Novartis, Sandoz Face 43-State Lawsuit Over Alleged Generic Drug Price-Fixing Conspiracy

A coalition of 43 state attorneys general has filed a sweeping lawsuit accusing pharmaceutical giant Novartis and its former subsidiary Sandoz of orchestrating a massive bid-rigging scheme for 31 generic drugs, calling it one of the most brazen conspiracies ever uncovered in the industry.

Feb 5, 2026

Business

India's Pharma Giants Poised to Slash Costs of Ozempic-Style Weight-Loss Drugs

As a key patent expires, India's massive pharmaceutical industry is preparing to flood the market with generic versions of blockbuster weight-loss drugs like Ozempic, potentially cutting prices by up to 90% and reshaping access to obesity treatments globally.

Feb 8, 2026

Business

Catalyst Pharmaceuticals Navigates Portfolio Shifts: Firdapse Drives Growth, Agamree Gains Ground Amid Fycompa Generic Pressure

In a recent analyst discussion, Catalyst Pharmaceuticals outlined a strategic focus on its rare disease franchises. While flagship drug Firdapse shows robust expansion potential, newer launch Agamree is building traction in Duchenne muscular dystrophy. The company is concurrently managing the expected decline of anti-epileptic Fycompa following generic entry, leveraging a strong cash position for future business development.

Mar 15, 2026

Business

Novo Nordisk's Wegovy Gains Higher EU Dose Approval as Generic Competition Looms in India

The European Commission has approved a higher maintenance dose for Novo Nordisk's blockbuster obesity drug Wegovy, while Dr. Reddy's Laboratories prepares a lower-cost generic version for the Indian market. These moves highlight the dual forces of market expansion and pricing pressure shaping the global anti-obesity drug landscape.

Feb 18, 2026

Beyond the Pump: How Middle East Tensions Threaten Global Access to Generic Medicines

The ongoing conflict in Iran, disrupting critical shipping lanes, is poised to ripple through pharmaceutical supply chains, with experts warning of impending cost increases for essential generic drugs.

Mar 11, 2026

Business

Esperion Therapeutics Secures Key Patent Protections, Bolstering Long-Term Outlook for Heart Drugs

The Michigan-based biopharma firm has inked another settlement to delay generic competition for its flagship cholesterol medications until 2040, as it reports strong sales growth and pursues an ambitious expansion plan.

Mar 4, 2026

World

India's Generic Weight-Loss Drug Surge Poised to Reshape Global Obesity Fight

With a key patent expired, Indian pharmaceutical giants are set to flood the market with low-cost versions of blockbuster drugs like Ozempic, dramatically widening access to treatment and challenging the high-price status quo in global healthcare.

Mar 20, 2026

Business

TrumpRx Savings Plan: A 'Sideshow' for Most, Experts Warn, as Alternatives Offer Broader Relief

While the Trump administration touts its new drug discount platform, health policy analysts caution that the plan's benefits are narrow and may mislead consumers. We break down who might save—and the more reliable strategies for most Americans to cut prescription costs.

Feb 13, 2026

Business

Novartis Beats Profit Target Ahead of Schedule, Charts Course Through Generic Headwinds

The Swiss pharma giant reported robust 2025 results, hitting a key profitability goal early. While facing near-term pressure from U.S. generic competition, CEO Vas Narasimhan outlined a strategy anchored by a portfolio of growth brands and a promising late-stage pipeline.

Feb 5, 2026

Business

Australian Court Sides with AstraZeneca, Blocks Pharmacor's Generic Diabetes Drug Launch

A Federal Court injunction has halted Pharmacor's planned launch of generic dapagliflozin, handing AstraZeneca a key interim victory in a high-stakes patent battle over its blockbuster diabetes drug Forxiga.

Feb 17, 2026

Business

Biocon Bets Big on Generic Weight-Loss Drugs, Eyes Global Expansion Amid Cautious Home Market Approach

Indian pharmaceutical giant Biocon is positioning itself for a major revenue surge by launching generic versions of blockbuster obesity drugs worldwide, while navigating a complex and price-sensitive landscape in its domestic market.

Feb 13, 2026

India's Generic Surge Poised to Democratize Global Access to Blockbuster Weight-Loss Drugs

As the patent on semaglutide expires, India's pharmaceutical giants are set to flood the market with affordable generics, potentially slashing costs and reshaping treatment for obesity and diabetes worldwide, amid calls for cautious regulation.

Mar 18, 2026

World

Trump's New Drug Price Website Launches with Narrow Focus, Heavy on Weight-Loss Drug Discounts

The Trump administration's newly launched prescription drug portal, TrumpRx.gov, is drawing scrutiny for its limited scope. While offering deep discounts on popular GLP-1 weight-loss medications, experts say the site's initial offerings fall short of a comprehensive solution for lowering drug costs for most Americans.

Feb 7, 2026

Business

South Korea's Pharma Overhaul: Pricing Reform Set for 2026-28 Sparks Industry Tension

South Korea's planned overhaul of its drug pricing system aims to control costs but has ignited fierce debate. While patented drugs may see moderate price adjustments compared to regional peers, the reform's focus on generics and off-patent medicines has domestic developers warning of market instability and threats to innovation funding.

Feb 13, 2026

Business

Novo Nordisk Escalates Legal Battle Against Telehealth Firms Over Compounded Weight-Loss Drugs

As the FDA declares shortages over, Novo Nordisk's lawsuit against Hims & Hers spotlights the fierce battle between pharmaceutical giants and telehealth companies selling cheaper, compounded versions of blockbuster GLP-1 drugs, raising critical questions about access, safety, and market competition.

Feb 22, 2026

Business

Wells Fargo Sees Amphastar's New Inhaler as Growth Engine, Despite Price Target Cut

While Wells Fargo trimmed its price target on Amphastar Pharmaceuticals, analysts highlight the recent FDA approval for its generic inhaler as a key catalyst for future revenue growth, even as near-term sales projections soften.

Mar 3, 2026

Business

Amneal Posts Strong Q4 Revenue Beat, but Cautious Full-Year Outlook Tempers Investor Enthusiasm

Amneal Pharmaceuticals (AMRX) reported fourth-quarter sales that surpassed Wall Street forecasts, driven by robust demand for its generic and specialty drugs. However, the company's revenue guidance for the coming year fell short of analyst expectations, presenting a mixed picture for the New Jersey-based drugmaker.

Feb 28, 2026

Business

Collegium Pharmaceutical Stock Slumps 7.4% Despite Reaffirming 2026 Sales Outlook

Shares of Collegium Pharmaceutical fell sharply following its Q4 2025 earnings report, which revealed a profit miss even as the company posted record revenue and stood by its 2026 product sales forecast of $805-$825 million. The market's reaction highlights investor concerns over product concentration and future generic competition.

Feb 28, 2026

Business

Amphastar Navigates Legacy Product Headwinds, Bets on New Launches and Pipeline for 2026 Growth

While facing pricing pressure on key legacy drugs, Amphastar Pharmaceuticals sees a path to mid-to-high single-digit revenue growth in 2026, fueled by recent FDA approvals like Ipratropium Bromide and the sustained strength of its flagship product BAQSIMI.

Feb 27, 2026